NDAORALSUSPENSION
Approved
Apr 2016
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Mechanism of Action
AMPA Receptor Antagonists
Pharmacologic Class:
Noncompetitive AMPA Glutamate Receptor Antagonist
Clinical Trials (5)
A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures
Started Nov 2024
110 enrolled
Partial-Onset SeizuresPrimary Generalized Tonic-clonic Seizures
A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures
Started Oct 2022
125 enrolled
Epilepsy
Fycompa in Catamenial Epilepsy
Started Mar 2022
7 enrolled
Catamenial Epilepsy
Perampanel Titration and Cognitive Effects
Started Oct 2021
29 enrolled
Epilepsy
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
Started Nov 2020
12 enrolled
Glioma, MalignantSurgerySeizures
Loss of Exclusivity
LOE Date
Jul 1, 2026
4 months away
Patent Expiry
Jul 1, 2026
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8772497 | Jul 1, 2026 | Substance | — |